AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Synlogic Announces First Quarter 2019 Conference Call and Webcast

May 2, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2019--Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market closes on Thursday, May 9, 2019. The press release will be followed by a conference call at 5:00 pm ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. The conference ID number for the call is 2154739. Participants may access the live webcast via a link on the Synlogic website in the Events Calendar of the Investors and Media section. For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Company’s website.

About Synlogic

Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease. Synthetic Biotic medicines are designed to act locally and have a systemic effect to address disease in patients. Synlogic’s two lead programs, SYNB1020 and SYNB1618, are orally administered and target hyperammonemia as a result of liver damage or genetic disease, and phenylketonuria, respectively. Synlogic is also developing SYNB1891 as an intratumorally-administered Synthetic Biotic medicine for the treatment of cancer. In addition, the company is leveraging the broad potential of its platform to create additional Synthetic Biotic medicines for the treatment of liver disease, as well as inflammatory and immune disorders including Synlogic’s collaboration with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190502005712/en/

CONTACT: Media Contact:

Synlogic

Courtney Heath

617-872-2462

courtney@scientpr.com

Investor Contact:

Synlogic

Elizabeth Wolffe, Ph.D.

617-207-5509

liz@synlogictx.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH

SOURCE: Synlogic, Inc.

Copyright Business Wire 2019.

PUB: 05/02/2019 04:05 PM/DISC: 05/02/2019 04:06 PM

http://www.businesswire.com/news/home/20190502005712/en